|
?:abstract
|
-
At the end of 2019, novel coronavirus (COVID-19) infection was detected in Wuhan City, Hubei Province, China The COVID-19 infection characteristics include a long incubation period, strong infectivity, and high fatality rate, and it negatively affects human health and social development COVID-19 has become a common problem in the global medical and health system It is essentially an acute self-limiting disease Patients with severe COVID-19 infection usually progress to acute respiratory distress syndrome, sepsis, metabolic acidosis that is difficult to correct, coagulation dysfunction, multiple organ failure, and even death within a short period after onset There remains a lack of effective drugs for such patients clinically Mesenchymal stem cells (MSCs) are expected to reduce the risk of complications and death in patients because they have strong anti-inflammatory and immunomodulatory capabilities, which can improve the microenvironment, promote neovascularization, and enhance tissue repair capabilities China is currently conducting several clinical trials on MSCs for the treatment of COVID-19 Here, we review the research progress related to using stem cells to treat patients with COVID-19
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}